文档介绍：阿立哌唑与***治疗首发精神分裂症对照研究
(作者:___________单位: ___________邮编: ___________)
【摘要】目的探讨阿立哌唑与***治疗首发精神分裂症的临床疗效与安全性。方法将60例首发精神分裂症患者随机分为两组各30例,研究组口服阿立哌唑治疗,对照组口服***治疗,观察6 w。于治疗前及治疗2 w、4 w、6 w末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗6 %,%,两组显效率无显著性差异(P>)。治疗2 w末起两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降(P<),同期两组间比较均无显著性差异(P>)。两组不良反应均轻微,研究组静坐不能、体重增加、月经改变及泌乳发生率显著低于对照组,但差异无显著性(P>)。结论阿立哌唑治疗精神分裂症的疗效与***相当,但对内分泌系统影响较***小。
【关键词】精神分裂症;阿立哌唑;***;阳性与阴性症状量表;副反应量表
【Abstract】 Objective To explore the clinical efficacy and safety of aripiprazole in the treatment of first-episode schizophrenia. Methods Sixty schizophrenics were randomly divided into research group(n=30) taking orally aripiprazole and control group(n=30) doing risperidone for 6 weeks. Clinical efficacies were assessed with the Positive and Negative Symptom Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) before treatment and at the ends of the 2nd, 4th and 6th week At the end of the 6th week, obviously effective rates were % in the research and % in the control group respectively, which showed no difference(). The total and all factors
’ scores of the PANSS for both groups lowered more significantly since the end of the 2nd pared pretreatment( or ) ; there were no significant differences in synchronization parisons().Adverse reactions of